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Abstract
Background: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen
receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated
with Ki67 value change after CNB.
Methods: A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples
(SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed
to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were
classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value
change was calculated as SRS minus CNB.
Results: Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation
between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples:
29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype
were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal
B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 %
within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+
tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed
in patients with STI ≥ 5 days.
Conclusion: CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly
increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to
consider Ki67 changes following CNB among different breast cancer molecular subtypes.
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Background
Core needle biopsy (CNB) is recommended for an initial
breast cancer pathological diagnosis and is used to
evaluate estrogen receptor (ER), progesterone receptor
(PR), and HER2 status [1]. Microarray data have identi-
fied that breast cancer is comprised of at least five mo-
lecular subtypes: Luminal A, Luminal B, triple negative
(TN), HER2 positive and normal-like [2]. The 2013 St.
Gallen breast cancer consensus recommends using ER,
PR, HER2, and Ki67 results to classify breast cancer into
molecular subtypes in order to guide systemic treatment
decision making [3]. Our previous study showed that
CNB had a high concordance rate in evaluating molecu-
lar subtype status compared with those in surgically
removal samples (SRS) [4].
With the development of new agents, “window of
opportunity” pre-surgical trials have been applied to test
their potential anticancer abilities and mechanisms in
breast cancer patients [5]. Patients in these trials are
usually treated with experimental agents for a relatively
short period compared with standard neoadjuvant sys-
temic therapy [6]. In this situation, response rate is no
longer suitable as an endpoint, so a breast cancer prolif-
eration biomarker, such as Ki67, is then applied to deter-
mine the new agent’s biologic effect [7]. Thus, a Ki67
change after two weeks of endocrine treatment, for
example, may predict response rates in a neoadjuvant
study [8]. In addition, a decrease of Ki67 after neoadju-
vant chemotherapy or endocrine therapy seems also to
be related to a good prognosis [9, 10].
However, tumor heterogeneity, sample fixation, and
CNB methods can cause discordance of biomarkers evalu-
ation between CNB and SRS [4]. Also, Ki67, compared
with ER, PR, and HER2, is reported to have only a fair to
moderate agreement between CNB and SRS, especially in
ER+/Luminal breast cancers [11, 12]. Furthermore, several
studies have demonstrated that Ki67 expression will in-
crease after CNB, which may be caused by biopsy stimula-
tion, arguing that this Ki67 change needs to be considered
in clinical practice as well as in “window of opportunity”
trials [11, 13]. However, there are limited data about which
factors are associated with Ki67 change after CNB. There-
fore, we performed a comprehensive analysis to find
which factor(s) can influence Ki67 change after CNB in
early breast cancer patients.
Methods
Patient population
Consecutive breast cancer patients who received CNB
and followed by surgery in Ruijin Hospital, Shanghai
Jiaotong University School of Medicine between Oct.
2009 and Feb. 2012 were retrospectively analyzed. All
enrolled patients needed paired CNB and SRS samples.
Patients with large tumor were likely to receive CNB by
surgeon’s choice. Ultrasound was applied to guide the
CNB procedure, with more than three 14-gauce CNB
samples being collected for pathological examination.
CNB and SRS samples were fixed in 10 % neutral buff-
ered formalin within 30 min after tumor removal, and
fixation intervals ranged from at least 6 h to 24 h for
CNB and at least 6 h to 48 h for SRS samples. Patients’
enrollment criteria were described in our previous report
[11]. In addition, CNB and surgery dates were retrieved
to calculate the surgery time interval (STI) after CNB.
Twenty-two patients with STI more than 60 days were
further excluded. All participants gave written informed
consent before inclusion. The independent Ethical
Committee/Institutional Review Board of Ruijin Hospital,
Shanghai Jiaotong University School of Medicine reviewed
and approved this study protocol, which was conducted in
accordance with the Declaration of Helsinki.
Breast cancer molecular subtype classification
The methods and positivity criteria for immunohisto-
chemical (IHC) assessment of ER, PR, HER2, and Ki67
were described in our previous report, all of which were
performed in the Department of Pathology, Ruijin
Hospital, Shanghai Jiaotong University School of Medicine
[11]. In brief, Ventana Autostain System (BenchMark XT,
Ventana Medical Systems, Inc., Tucson, AZ) was used to
stain the paired CNB and SRS, which were further evalu-
ated by two senior pathologists (X. Fei, and X. Jin).
Tumors with more than 1 % positive invasive cell nuclear
staining were classified as ER+ or PR+. The 2007 ASCO/
CAP (American Society of Clinical Oncology/College of
American Pathologists) guidelines were applied in the
HER2 status evaluation. Either HER2 IHC 3+ or fluores-
cence in situ hybridization positivity was regarded as
HER2 positive (HER2+) [14]. For Ki67 expression scoring,
we used the same method for calculating CNB and SRS
samples. Cell distribution over the entire slice was first
reviewed and 500-2000 cells were chosen from different
microscopic views if the Ki67 expression distribution was
uniform. Otherwise, 2000 cells were equally counted in
both hotspot and negative areas in slice. Ki67 expression
was scored as the percentage of positive invasive tumor
cells with any nuclear staining and recorded as mean per-
centage of positive cells [11]. Histo-pathological parame-
ters and receptor status in CNB were set as the baseline.
Ki67 change between CNB and SRS was calculated by
using CNB as the baseline.
Hormonal receptor negativity (HR-) was defined as
both ER- and PR-. The concordance rate for molecular
subtype classification between CNB and SRS was similar
by using a Ki67 value of either 14 % or 20 %, while the
latter had the higher κ value [11]. Also, 20 % was the
mean value for HR+/HER2- patients and the median
value for all patients in CNB samples. Thus, 20 % was
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selected as the Ki67 cutoff value in determining Luminal
status. Five breast cancer molecular subtypes were clas-
sified according to the 2013 St. Gallen breast cancer
consensus [3]: Luminal A (ER+/HER2–, Ki67 < 20 % and
PR ≥20 %), Luminal B-HER2- (ER+/HER2-, Ki67 ≥ 20 %
or ER+/HER2-, PR < 20 %, or ER-/PR+/HER2-), Luminal
B-HER2+ (HR+/HER2+), TN (HR-/HER2–) and HER2+
(HR-/HER2+).
Statistical analysis
Kappa test was applied to test concordance rates for ER,
PR, HER2, and molecular subtypes between CNB and
SRS. Values of κ > 0.6 were correlated with good agree-
ment, values between 0.4 and 0.6 considered moderate
agreements, values < 0.4 corresponded to fair, and
values < 0.2 reflected poor agreement. Ki67 change
after CNB was compared by using two paired samples
t test. Chi-square test was used to calculate the asso-
ciation between STI and tumor characteristics. ANOVA
analysis was performed to calculate the relationship be-
tween Ki67 change and potential influencing factors includ-
ing: age, menopausal status, surgery type, histopathology,
tumor grade, tumor size, lymph node status, ER, PR, HER2,
molecular subtype, and STI. Multivariate ANOVA analysis
was then done to find the association and interaction
between Ki67 change and these factors. The SPSS
statistical software package (version 13.0; SPSS Com-
pany, Chicago, IL) was used in the statistical analysis




A total of 276 breast cancer patients were enrolled. Mean
age was 56.6 (24-91) years. Ninety percent of patients were
diagnosed with invasive ductal carcinoma and 32.6 % had
grade III tumors. There were 214 (77.5 %) and 163
(59.1 %) of cases with ER and PR positive disease. Fifty-
nine (21.4 %) had HER2+ breast cancer. Mean Ki67 value
was 26.2 % (1-90 %) in CNB samples, and 53.3 % tumors
were classified as Ki67 high expression. There were 73
(26.4 %), 109 (39.5 %), 33 (12.0 %), 35 (12.7 %), and 26
(9.4 %) patients classified as Luminal A, Luminal B-HER2-,
Luminal B-HER2+, TN, and HER2+ subtype, respectively.
Mean STI after CNB was 4.5 (1-37) days. Ten patients had
STI of more than 10 days. The first, second, and third
quartile days of STI were 3, 4, and 5 days, respectively.
Next, we categorized STI as following groups: less than
3 days (55 patients), 3-4 days (113 patients), more than
4 days (108 patients) (Table 1). Table 2 shows STI
categorized versus initial tumor characteristics as well
as patient characteristics. There was no association
between STI groups and clinic-pathological character-
istics. Regarding Ki67 expression level at CNB and at
surgery versus patients’ time to surgery, there was no
significant correlation between Ki67 expression level
and STI (Fig. 1a and b).
Comparison of receptor status and Ki67 results between
CNB samples and SRS
Concordance rates of ER, PR, and HER2 between
CNB and SRS were 94.2 %, 87.0 % and 97.1 %. Kappa
test showed κ values were 0.841, 0.729, and 0.914, re-
spectively, demonstrating good overall agreement.
Additionally, good agreement was observed for HR
test, with a concordance rate of 94.2 % (κ = 0.837). In
terms of molecular subtype analysis, the overall concord-
ance rate was 72.5 %, with κ value of 0.630, also regarded
as a good agreement.
Ki67 expression value was much higher in SRS com-
pared with CNB samples by using two paired samples t
test, with mean values of 29.1 % and 26.2 %, respectively
(P < 0.001). Using 20 % as the cutoff value for a high
level of Ki67 expression, the concordance rate was
80.4 %, with κ value of 0.60. TN breast cancer had the
highest Ki67 value of all subtypes. Median and mean
Ki67 change was 0 (inter-quartile range (IQR), -4.5 %,
10 %) and 2.9 % (±13.2 %), respectively.
Factors associated with Ki67 change analysis
Univariate ANOVA analysis was used to determine
whether patient characteristics and STI were associ-
ated with Ki67 changes. Both breast cancer molecular
subtype and STI were significantly associated with
Ki67 change after CNB, while other host and tumor
characteristics had no influence (Figs. 2, 3, Table 3).
Fig. 1c shows Ki67 change after CNB versus patients’
STI. Most cases had Ki67 change between -20 % and
20 % after CNB. Mean Ki67 change with different
STIs after CNB was: -1.1 % (1-2 days STI), 2.1 % (3-4
days STI), 5.6 % (≥5 days STI), respectively (P = 0.007,
Table 4). Subgroup analysis showed that patients
receiving surgery more than 4 days after CNB had a
higher Ki67 increase compared with those treated
with surgery within 2 days (P = 0.006). Besides, we
classified STI into another 5 groups: 1-2 days (n = 55),
3 days (n = 50), 4 days (n = 63), 5 days (n = 52), and ≥
6 days (n = 56). ANOVA analysis still showed that Ki67
change after CNB was significantly associated with
STI (P = 0.01, Additional file 1: Figure S1). Luminal B-
HER2- tumors, which had a higher baseline Ki67 value
than Luminal A disease, showed a Ki67 decrease after
CNB. However, other breast cancer subtypes showed an
increased Ki67 value, with a mean Ki67 absolute increase
from 3.3 % to 6.2 % (Table 5). Subgroup comparison
showed that Luminal A tumors had a higher Ki67 value
increase after CNB than Luminal B-HER2- (P = 0.014).
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Multivariate ANOVA analysis demonstrated that STI
and molecular subtype were still significantly associated
with Ki67 change after CNB, with P values of 0.010 and
0.042, respectively. Subgroup test showed that there was
a slight trend of interaction between STI and molecular
subtype for Ki67 change (P = 0.220). Furthermore, we
analyzed Ki67 changes among various subtypes with dif-
ferent STI (Fig. 4). For HER2+ or TN patients, Ki67
change was apt to be 0 among those receiving surgery
within 4 days after CNB, while the Ki67 value increase
was 11.5 % and 7.7 %, respectively, in those with a STI
of more than 4 days (Fig. 4).
Discussion
Our present study demonstrated that CNB was accurate
in evaluating breast cancer receptor and molecular
subtype status compared with subsequent SRS. More
importantly, we found that both STI and molecular sub-
type were associated with Ki67 changes after CNB.
Luminal A tumors had more Ki67 elevation than did
Luminal B-HER2- tumors. The Ki67 value increase was
much more obvious in patients with prolonged STI. TN
or HER2+ breast cancer patients were more likely to ex-
perience a significant Ki67 increase with a long surgery
waiting time.
CNB has been proven to be a minimally invasive and
accurate method in preoperative pathological diagnosis
[15], and can provide sufficient tissue for breast cancer
biomarkers analysis, including ER, PR, HER2, and Ki67
[1]. Meta-analysis has shown that CNB is reliable in test-
ing ER, PR, and HER2 status compared with SRS [4].
Moreover, CNB has good agreement with SRS in breast
cancer molecular subtype analysis in determining ER,
PR, HER2, and Ki67 results [11]. There is no consensus
concerning the Ki67 cutoff value for high proliferation
[3]. In our study, we used the 20 % as the cutoff value,
the median value in CNB samples and which had a rela-
tively high concordance rate for molecular subtype
Table 1 Baseline patient characteristics
Characteristic No. Percent









Mastectomy (+/−reconstruction) 239 86.6
Lumpectomy 37 13.4
Pathological type
Invasive ductal carcinoma 246 89.1




≤2 cm 118 42.8
2-5 cm 147 53.3





















Ki67 (%, mean) 26.2 (1-90)
<20 129 46.7
≥20 147 53.3
Table 1 Baseline patient characteristics (Continued)
Molecular subtype
Luminal A 73 26.4
Luminal B-HER2- 109 39.5
Luminal B-HER2+ 33 12.0
Triple negative 35 12.7
HER2 positive 26 9.4




Abbreviation: NA not available
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analysis between CNB and SRS. The 2013 St. Gallen
breast cancer consensus of 20 % Ki67 cutoff value was
then applied to classify patients into various molecular
subtypes. Our concordance analysis demonstrated that
CNB was accurate in determining molecular subtype sta-
tus compared with SRS.
Ki67, a well-established proliferation marker, is used to
determine specific breast cancer Luminal subtypes [16].
For early breast cancer patients, high Ki67 expression is
associated with a poor outcome [17]. Several retrospect-
ive studies have found that Ki67 could predict endocrine
treatment and chemotherapy response in ER+ breast
cancer patients [8, 18]. In addition, Ki67 is a key prolif-
eration marker for calculating breast cancer recurrence
score in the Oncotype-DX assay [19]. However, several
studies have found that there was only fair to moderate
agreement for Ki67 testing between CNB and SRS, and
that the κ value was much lower than ER, PR, and HER2
evaluation; this was mainly interpreted as sampling error
or tumor heterogeneity [11, 12]. Most studies have dem-
onstrated that Ki67 expression will increase after CNB,
possibly due to wound healing [20] or sample fixation
intervals difference between CNB and surgically removed
samples, which warrants further study. Our current data
also showed a significantly higher Ki67 expression value in
SRS compared with CNB samples (29.1 % vs. 26.2 %).
In preoperative “window of opportunity” clinical
studies, Ki67 is often used as a surrogate biomarker
to evaluate new anticancer drug anti-proliferation
ability [7]. Patients treated with neoadjuvant endo-
crine therapy have a higher response rate if they ex-
perience a Ki67 decrease after 2 weeks therapy [8].
However, all such studies omitted Ki67 change after
CNB, which may result in a shift of efficacy analysis.
We analyzed potential clinic-pathological factors asso-
ciated with Ki67 change after CNB to determine if
any subgroup might change significantly and found
that breast cancer molecular subtype was, indeed, an
independent factor. Patients with different subtypes





≥5 days P value
Age 0.067
<40 5 5 10
40-49 16 24 24
50-70 32 70 53
>70 2 14 21
Menstrual status 0.084
Peri/pre-menopause 24 30 35
Post-menopause 31 83 73




Lumpectomy 8 15 14
Pathological type 0.973
Invasive ductal carcinoma 49 101 96
Invasive lobular carcinoma 3 5 4
Others 3 7 8
Tumor size 0.110a
Tx 2 2 1
≤2 cm 30 45 43
2-5 cm 23 65 49
>5 cm 0 1 5
Axillary lymph node 0.582
Negative 28 67 60
Positive 27 46 48
Histologic grading 0.821a
I 0 3 3
II 30 51 53
III 15 41 34
NA 10 18 18
Estrogen Receptor 0.732
Negative 11 28 23
Positive 44 85 85
Progesterone Receptor 0.357
Negative 21 52 40
Positive 34 61 68
Hormonal Receptor 0.822
Negative 11 27 23
Positive 44 86 85
HER2 0.797
Negative 43 91 83
Positive 12 22 25
Ki67 (%, mean) 0.222
<20 20 55 54
Table 2 Surgery time interval and tumor characteristics
(Continued)
≥20 35 58 54
Molecular subtype 0.738
Luminal A 13 30 30
Luminal B-HER2- 26 43 40
Luminal B-HER2+ 5 13 15
Triple negative 4 18 13
HER2 positive 7 9 10
Abbreviation: NA not available
aCalculated by Fisher’s exact test
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did have various Ki67 changes, indicating that Ki67
change seemed to be associated with its specific
tumor biologic behavior. In neoadjuvant treatment of
HER2-positive breast cancer, gene expression profiling
analysis has demonstrated that subtype status can sig-
nificantly change after treatment. Luminal B or
HER2-enriched tumors on CNB could become Lu-
minal A, perhaps due to cell reprogramming, stromal
alteration, or heterogeneity. Luminal A tumors on
CNB had more discordant cases and changes to other
subtypes in SRS [21]. Our present study showed that
Luminal A tumors had a higher Ki67 increase after
CNB compared with Luminal B-HER2-, perhaps also
reflecting wound healing, stromal reaction, or tumor
heterogeneity. This indicates that further translational
research needs to interpret anti-proliferation efficacy
among the different molecular subtypes.
It has been reported that Ki67 changes after CNB were
more obvious in TN or HER2+ breast cancer, but that
there was no significant Ki67 increase in the luminal
subtypes [13]. The major difference between the two
studies was STI after CNB. There were 41 days in that
study, much longer than in our study, which had a mean
of only 4.5 days. Although, no significant Ki67 changes
were noted over time after CNB in that study, we here
report that STI after CNB is significantly associated with
Ki67 change. Thus, breast cancer patients with longer
surgery waiting time after CNB had a higher chance of
Ki67 increases. Furthermore, we analyzed whether STI
had different effects on Ki67 change among the breast
cancer molecular subtypes. Ki67 change was apt to be 0
in TN and HER2 breast cancer patients treated with
surgery within 4 days after CNB, while this was ≥ 7 % in
patients with STI more than 4 days, similar to the other
Fig. 1 Ki67 expression level and change distribution at different surgery time intervals. a): Ki67 expression level of core needle biopsies versus
surgery time intervals; b): Ki67 expression level at surgically removed samples versus surgery time intervals; c): Ki67 change distribution versus
surgery time intervals
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study. Although Ki67 increase after CNB has not been
reported to cause a worse disease outcome, its increase
has still been associated with chemotherapy sensitivity
[10]. Moreover, a long interval between surgery and adju-
vant chemotherapy has been reported to cause a worse
prognosis in HER2+ and TN breast cancer patients [22].
Taken together, our data support that TN or HER2+
breast cancer patients may need to be treated with surgery
within a short interval after CNB, and that neoadjuvant
systemic therapy may be a reasonable option for these
patients if they must wait a long time for surgery [23].
There were several limitations in our study. First, the
number of enrolled patients was not large enough to
further explore subgroup analysis differences, especially
for subgroup interaction effect analysis. There were
relatively few patients in separate subgroups regarding
various STI and molecular subtype combinations. In
addition, most patients were treated with surgery with a
Fig. 2 Surgery time interval and Ki67 change after core needle biopsy
Fig. 3 Molecular subtypes and Ki67 change after core needle biopsy
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very short waiting time after CNB, which may be differ-
ent from other centers. In our center, we firstly did diag-
nostic hematoxylin and eosin staining for tumor within
24 h after biopsy in the in-patient ward, and further
surgery was arranged for most patients when invasive
breast cancer was found. ER, PR, and HER2 status
results was not mandatory before surgery. For other
centers with longer waiting periods after biopsy, in
which IHC or FISH analysis was done before surgery,
one would to consider the STI differences in order to
compare our results to theirs. Our mean STI was
4.5 days and only 3 separate groups were constructed
with different STIs. We have not further categorized
patients into another group with longer STI because
there were only 10 patients with STI of more than
10 days. This prevented our study from being able to
answer whether Ki67 change would be decreased in
specific subtypes with a prolonged surgical waiting
period. Finally, HER2 status was only evaluated by the
2007 edition of ASCO/CAP criteria, with there being
a slight difference with new edition of ASCO/CAP
recommendation [24]. However, we doubt that this
would change our results.
Conclusion
Our study has demonstrated that CNB is accurate in
evaluating ER, PR, HER2, and molecular subtype status
in breast cancer. Ki67 value can significantly increase
after CNB, and this is associated with STI and molecular
subtype. Luminal A tumors experienced more Ki67 ele-
vation than did Luminal B-HER2-. Breast cancer patients
Table 3 Univariate analysis of Ki67 change and clinic-pathological
factors









Surgery time interval 0.007
aExpression status in CNB sample
Univariate ANOVA analysis used to analyze association between Ki67 change
and clinico-pathological factors
Table 4 Ki67 expression and change value at CNB and SRB in
different surgery time intervals
No. Median Ki67 % (IQR) Mean Ki67 % (SD)
All populations 276
CNB 20 (10, 40) 26.2 (22.0)
SRS 25 (10, 40) 29.1 (22.0)
Ki67 changea 0 (-4.5. 10) 2.9 (13.2)
1-2 days 55
CNB 20 (10, 40) 27.7 (21.0)
SRS 20 (10, 40) 26.6 (19.1)
Ki67 changea 0 (-10, 5) -1.1 (11.0)
3-4 days 113
CNB 20 (10, 50) 28.4 (24.6)
SRS 25 (10, 50) 30.5 (23.0)
Ki67 changea 0 (-5, 10) 2.1 (15.2)
≥5 days 108
CNB 17.5 (10, 30) 23.2 (20.8)
SRS 25 (10, 40) 28.8 (22.4)
Ki67 changea 5 (0, 10) 5.6 (11.4)
aKi67 change, SRS minus CNB
Abbreviation: CNB core needle biopsy, IQR inter quartile range, SRS surgically
removed samples, SD standard deviation
Table 5 Ki67 expression and change value of CNB and SRS
among molecular subtypes
No. Median Ki67 (IQR) Mean Ki67(SD)
Luminal A 73
CNB 10 (5, 10) 8.2 (4.1)
SRS 10 (10, 20) 14.5 (9.6)
Ki67 changea 5 (0, 10) 6.3 (8.6)
Luminal B HER2- 109
CNB 20 (10, 40) 26.9 (19.5)
SRS 20 (10, 30) 26.9 (19.2)
Ki67 changea 0 (-10, 10) -0.1 (12.8)
Luminal B HER2+ 33
CNB 20 (10, 50) 30.2 (20.7)
SRS 30 (15, 55) 33.5 (20.0)
Ki67 changea 0 (-10, 14.5) 3.3 (15.1)
Triple negative 35
CNB 60 (30, 80) 54.1 (26.4)
SRS 70 (30, 80) 57.4 (25.8)
Ki67 changea 0 (-10, 10) 3.3 (13.5)
HER2 positive 26
CNB 25 (20, 40) 31.2 (17.3)
SRS 30 (23.75, 50) 35.4 (15.1)
Ki67 changea 5 (-1.25, 20.0) 4.2 (19.6)
aKi67 change, SRS minus CNB
Abbreviation: CNB core needle biopsy, IQR inter quartile range, SRS surgically
removed samples, SD standard deviation
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with longer STI had a higher Ki67 increase after CNB.
TN and HER2+ breast cancer patients with longer STI
had a higher degree of Ki67 increase, while this is 0 with
a short STI. We propose that anti-proliferation efficacy
of anti-cancer agents needs to be evaluated among
different subtypes in preoperative translational trials.
Patients with TN or HER2+ breast cancer probably need
to be treated with a short STI or primary systemic ther-
apy after CNB, but this warrants further validation.
Additional file
Additional file 1: Figure S1. Mean Ki67 change after core needle
biopsy among different 5 surgery time interval groups. (TIFF 39 kb)
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